ADC Therapeutics
- Country
- 🇨ðŸ‡Switzerland
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 274
- Market Cap
- $295.7M
- Introduction
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded b...
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
- Conditions
- Interventions
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 56
- Registration Number
- NCT05660395
- Locations
- 🇧🇷
Hospital SÃrio-Libanês - BrasÃlia, BrasÃlia, Brazil
🇧🇷Hospital SÃrio-Libanês - São Paulo, São Paulo, Brazil
🇰🇷Kyungpook National University Chilgok Hospital, Daegu, Daegu Gwang'yeogsi, Korea, Republic of
A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants with Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-05-25
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 260
- Registration Number
- NCT05389462
- Locations
- 🇺🇸
Sarah Cannon at University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
🇺🇸Vanderbilt University Medical Center (VUMC) - Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸Sarcoma Oncology Research Center, Santa Monica, California, United States
Long-term Registry of Patients Treated With Loncastuximab Tesirine
- Conditions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- ADC Therapeutics S.A.
- Registration Number
- NCT05160064
- Locations
- 🇺🇸
Compassionate Cancer Care Medical Group, Fountain Valley, California, United States
A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 41
- Registration Number
- NCT05144009
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇵🇷Hospital Español Auxilio Mutuo, San Juan, Puerto Rico
🇺🇸New York Cancer & Blood Specialists - New Hyde Park, Babylon, New York, United States
A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8)
- Conditions
- Interventions
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- ADC Therapeutics S.A.
- Registration Number
- NCT04974996
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 132
- Registration Number
- NCT04972981
- Locations
- 🇪🇸
Universidad Complutense de Madrid - Hospital Universitario 12 de Octubre, Madrid, Spain
🇬🇧Imperial College Healthcare NHS Trust - St Mary's Hospital, London, England, United Kingdom
🇬🇧Sarah Cannon Research Institute (SCRI) - London (SCRI-UK), London, England, United Kingdom
A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 200
- Registration Number
- NCT04970901
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Miami Cancer Institute, Miami, Florida, United States
🇺🇸Memorial Cancer Institute - Memorial Hospital West, Pembroke Pines, Florida, United States
Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2021-01-12
- Last Posted Date
- 2021-05-12
- Lead Sponsor
- ADC Therapeutics S.A.
- Registration Number
- NCT04705454
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2021-01-07
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 6
- Registration Number
- NCT04699461
- Locations
- 🇬🇧
Account University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇪🇸Hospital Universitario La Paz, Madrid, Spain
🇪🇸Hospital Universitario Virgen del RocÃo, Sevilla, Spain
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- ADC Therapeutics S.A.
- Target Recruit Count
- 350
- Registration Number
- NCT04384484
- Locations
- 🇺🇸
University of California San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Redlands Community Hospital, Redlands, California, United States
🇺🇸The Oncology Institute of Hope and Innovation, Whittier, California, United States